Andreas Galanopoulos NEUROLOGIST

• The role of the endogenous cannabinoid system in behavioural and neurobiological aspects of cognition. An experimental study in rats.

• Member of the European Academy of Neurology
• Member of the International Parkinson and Movement Disorder Society
• Member of the Hellenic Neurological Association
• Member of the Athens Association of Alzheimer’s Disease and Related Disorders

• Neurologist at the HYGEIA Hospital since 2012
• Private neurological office in Pallini, Attiki, since 2008
• Resident at the Neurology Department of the General Hospital of Piraeus “o Ag. Panteleimon”, 2004-2008
• Resident at the 2nd Psychiatry Department of Psychiatric Hospital of Chania, Crete, 2002-2003
• Participation in scientific activities of the Laboratory of Neurosciences and Behaviour, at Psychology Department of University of Crete, 2003-2004
• Resident at the 2nd Internal Medicine Department of the General Hospital of Athens “Elpis”, 2002
• Military service in the Hellenic Army as a doctor, 2000-2001
• Rural medical service at the Hospital of Molai, Lakonia, 1998-2000

Education Experience:

• Contribution in education of medical, biology, psychology undergraduate and postgraduate students

• Memory deficits – Alzheimer’s Disease and other types of dementia
• Multiple Sclerosis and other demyelinating disorders
• Parkinson’s Disease and movement disorders
• Headache, neuralgia and neuropathic pain
• Diseases of the Spinal Cord and Peripheral Nerves (neuritis and neuropathies)

Research Interest:

• Neurosciences-Brain neurotransmission
• Neurobiological mechanisms involved in memory and learning
• Cognition and Dementia
• Parkinson’s Disease and other neurodegenerative disorders

• WIN55,212-2 impairs non-associative recognition and spatial memory in rats via CB1 receptor stimulation. Pharmacol Biochem Behav. 2014 Sep;124:58-66,Galanopoulos A, Polissidis A, Georgiadou G, Papadopoulou-Daifoti Z, Nomikos GG, Pitsikas N, Antoniou K.,
• The effectiveness of memantine in a “behaviourally disturbed” AD population. Re-sults from a Greek observational, open-label, 6-month study. Journal of the Neuro-logical Sciences 333 (2013):e351, Galanopoulos A, Saltos L, Kerezoudi E, Parashos I
• Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioural output of acute D-amphetamine. Behav Brain Res. 2014 Aug 15;270:261-9, Polissidis A, Chouliara O, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, Antoniou K.
• The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently. Int J Neuropsychopharma-col. 2013 Mar;16(2):393-403, Polissidis A, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, An-toniou K
• Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dement Geriatr Cogn Disord. 2011;32(4):267-72, Forstl H, Stamouli SS, Janetzky W, Galanopoulos A, Karageorgiou C, Tzanakaki M.
• Δ(9)-THC and WIN55,212-2 affect brain tissue levels of excitatory amino acids in a phenotype-, compound-, dose-, and region-specific manner. Behav Brain Res. 2011 Oct 10;224(1):65-72, Galanopoulos A, Polissidis A, Papadopoulou-Daifoti Z, Nomikos GG, Antoniou K
• Extensive hypertensive encephalopathy completely reversed after successful treatment. European Journal of Neurology 17 (2010, Suppl. 3), 72–350, Galanopoulos A, Xifaras M, Polissidis A, Papadopoulou-Daifoti Z
• Ιndividual differences in the effects of cannabinoids on motor activity, dopaminer-gic activity and DARPP-32 phosphorylation in distinct regions of the brain. Int J Neuropsychopharmacol. 2010 Oct;13(9):1175-91, Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T, Marselos M, Papadopoulou-Daifoti Z, Nomikos GG, Spyraki C, Tzavara ET, Antoniou K
• Behavioural and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. Life Sci. 2009 Jul 31;85(5-6):248-54, Polissidis A, Chouliara O, Galanopoulos A, Marselos M, Papadopoulou-Daifoti Z, An-toniou K
• Behavioral pharmacological properties of a novel cannabinoid 1′,1′-dithiolane del-ta8-THC analog, AMG-3. Behavioural Pharmacology. 2005 Sep; 16(5-6):499-510. An-toniou K, Galanopoulos A, Vlachou S, Kourouli T, Nahmias V, Thermos K, Panagis G, Daifoti Z, Marselos M, Papahatjis D, Spyraki C.